AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03015090
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
Trial: NCT00677729
Drug: solution contains 1 mg salbutamol plus 3% hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
Trial: NCT03273972
Drug: Dosing
RxNorm normalized name: oral dosing devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be performed at the end of the visit following completion all other study visits
Trial: NCT00677729
Drug: solution contains 1 mg salbutamol plus 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
Trial: NCT01262911
Drug: SRT2379
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
Trial: NCT01262911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
Trial: NCT02530359
Drug: Placebo equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo equivalent per mouth
Trial: NCT02593851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution will be administered once or twice daily for 7 days.
Trial: NCT03651869
Drug: Cigarette 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Trial: NCT03651869
Drug: Cigarette 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Trial: NCT03651869
Drug: Patch 1
RxNorm normalized name: COVELET,PATCH 1.5IN X 2IN #0330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Trial: NCT03651869
Drug: Patch 2
RxNorm normalized name: COVERLET,EYE PATCH 2IN X 3IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Trial: NCT02467244
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
Trial: NCT04024137
Drug: ZSP1273 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 X 200-mg tablet taken orally
Trial: NCT04024137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets taken orally
Trial: NCT04024137
Drug: ZSP1273-400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 X 200-mg tablet taken orally
Trial: NCT04024137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet taken orally
Trial: NCT04024137
Drug: ZSP1273-600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 200-mg tablet taken orally
Trial: NCT04024137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets taken orally
Trial: NCT04024137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive matching placebo of ZSP1273
Trial: NCT01471522
Drug: Medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Trial: NCT03662568
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered RTV 100 mg orally three times daily in fed state
Trial: NCT02696616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03318562
Drug: eFT508
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg eFT508 dosed BID for 3 week cycles
Trial: NCT02921165
Drug: analgesic mouth rinses (dissolved Aspirin)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.
Trial: NCT02921165
Drug: Normal saline rinses.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
Trial: NCT01824758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
Trial: NCT01210001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching BI 10773 low dose
Trial: NCT01210001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching BI 10773 high dose
Trial: NCT00397579
Drug: DT388IL3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
Trial: NCT00544414
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005988
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005988
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005988
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00544414
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05845996
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous/subcutaneous injection
Trial: NCT00280267
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02531984
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04424901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose while hospitalized up to 9 days
Trial: NCT01133873
Drug: Propoxyphene napsylate (XP20C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
Trial: NCT01133873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 times a day in ascending doses until a maximum tolerated dose is identified
Trial: NCT02349165
Drug: Ricrolin TE
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
Trial: NCT01631864
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 was provided as 400 mg tablets.
Trial: NCT01631864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to LCZ696 and amlodipine.
Trial: NCT03164603
Drug: NLG802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
Trial: NCT01398384
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MI size at 48-72 hours
Trial: NCT01038570
Drug: Syntocinon®/- Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 sprays corresponding to 24 IU in each nostril
Trial: NCT03805269
Drug: wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wound infiltration: local anesthetics infiltration at surgical incision
Trial: NCT03619252
Drug: Standard Antibacterial Prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
Trial: NCT01501942
Drug: AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
Trial: NCT01501942
Drug: Buffered Saline
RxNorm normalized name: Phosphate Buffered Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo is an oral solution of phosphate buffered saline
Trial: NCT02134756
Drug: NutraStem Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01580878
Drug: Lotrimin Ultra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
Trial: NCT03868137
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of Ibuprofen 800 mg
Trial: NCT03868137
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02701634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT02655237
Drug: Leuprorelin Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin placebo-matching injections
Trial: NCT04068532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04068532
Drug: BIIB104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02280629
Drug: LT-02
RxNorm normalized name: LT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
Trial: NCT02280629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
Trial: NCT01572792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dose-matched placebo, twice per day
Trial: NCT03399526
Drug: Calcipotriene 0.005% ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment
Trial: NCT00269048
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01375101
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient is directed to use placebo capsule two times a day, ,until the one mouth
Trial: NCT02543411
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol
Trial: NCT00757601
Drug: MK1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK1006 capsules: 1 mg, 10 mg, and 20 mg.~Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose
Trial: NCT00757601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule to match MK1006 1, 10, and 20 mg.~Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose
Trial: NCT03089112
Drug: HGP1607
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period
Trial: NCT03089112
Drug: HGP1501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period
Trial: NCT02856178
Drug: F901318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
Trial: NCT03089112
Drug: HGP1607+HGP1501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period
Trial: NCT04362085
Drug: Therapeutic Anticoagulation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
Trial: NCT00144391
Drug: Transdermal Testosterone gel
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
Trial: NCT03656432
Drug: CPP-ACP paste
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
Trial: NCT01122771
Drug: liposomal amphotericin B + paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
Trial: NCT01122771
Drug: Miltefosine + Paromomycin
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
Trial: NCT02585765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weeks of daily placebo capsules.
Trial: NCT02753114
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Normal Saline administered via mucosal atomization device.
Trial: NCT00783237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray, single dose of 2 sprays per nostril
Trial: NCT02419105
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal gel, 75 mg daily
Trial: NCT02419105
Drug: Placebo drink solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drink solution, 0 IU Colecalciferol once per month
Trial: NCT02419105
Drug: Placebo transdermal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal gel, 0 mg testosterone daily
Trial: NCT01721993
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02211079
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of caffeine 100 mg (2\*50 mg tablets), on Day 1, 2, and 9.
Trial: NCT01673217
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02138682
Drug: l-123 Ioflupane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 millicuries of Ioflupane
Trial: NCT04626505
Drug: Placebo (ziltivekimab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered s.c. once every 4 weeks for 12 weeks
Trial: NCT00102908
Drug: Zoledronate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate placebo infusion
Trial: NCT00067236
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet, twice a day for 90 days
Trial: NCT01098721
Drug: WBI-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
Trial: NCT00297401
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO, up to 8 weeks
Trial: NCT02607072
Drug: Acetylsalicylic acid (ASA)/aspirin 200 mg daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02607072
Drug: Acetylsalicylic acid (ASA)/aspirin 100 mg daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02607072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00726700
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00726700
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02715947
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
Trial: NCT00920140
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
Trial: NCT00920140
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose will be maximum tolerated dose based on Phase I results.
Trial: NCT01770964
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03100500
Drug: QMF149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
Trial: NCT01466153
Drug: MEDI-551
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
Trial: NCT01021189
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
Trial: NCT01021189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution Dose single and followed by 7-day multiple dosing.
Trial: NCT00492869
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02143648
Drug: Placebo tablets BID
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets BID administered for 8 weeks
Trial: NCT00404313
Drug: MK0633
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
Trial: NCT00404313
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
Trial: NCT03153657
Drug: Piroxicam-Beta-Cyclodextrin
RxNorm normalized name: piroxicam-beta-cyclodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
Trial: NCT02099175
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m2/day - Powder for solution for infusion
Trial: NCT02998567
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In arm B2 (lung expansion) replacing guadecitabine
Trial: NCT03153657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
Trial: NCT01074710
Drug: [2-13C] uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po, in the form of semi-solid meal, granules, once a period
Trial: NCT01074710
Drug: [2-13C] uracil, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po, in the form of semi-solid meal, granules, once a period
Trial: NCT01202591
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet oral twice daily
Trial: NCT01202591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet oral twice daily
Trial: NCT01278849
Drug: ASA404
FDA approved: no
EMA approved: no
PMDA approved: no